Endpoints
SECONDARY
The primary objective of this study was to establish non-inferiority (a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3) for NET/LAT relative to BIM/TIM, and the primary efficacy outcome was a comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 16:00 h at Week 2, Week 6, and Month 3. Diurnal values were a mean of measurements taken during the day. Outcome comparisons of the study drugs were expressed as mean values and assessment of each time point was undertaken for the following secondary efficacy endpoints: diurnal IOP; change from diurnally adjusted baseline IOP at each study time point; change from baseline in mean diurnal IOP; percent change from diurnally adjusted baseline IOP; percentage change from baseline in mean diurnal IOP; and the percentage of patients achieving a pre-specified mean, mean change, and percentage mean change in diurnal IOP levels.